| poliovirus v. inactivated |
[USP] a suspension of formalin-inactivated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, administered intramuscularly or subcutaneously for immunization against poliomyelitis in infants, children, and adolescents, as well as adults at increased risk of exposure. Called also Salk v.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
|---|---|
| poliovirus v. live oral |
[USP] a live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture and used for immunization against poliomyelitis; administered orally. OPV induces both humoral and intestinal immunity and is excreted in the feces for at least several weeks after immunization. Because it can cause vaccine-associated paralytic poliomyelitis in those vaccinated and also their contacts, it is used only under special circumstances or in countries in which wild-type poliovirus has not been eradicated. OPV should not be administered to immunocompromised individuals or their household contacts. Called also Sabin v.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
| polioencephalitis hemorrhagica |
Polioencephalitis accompanied by hemorrhagic lesions.
Ãâó:
|
| poliovirus vaccine, inactivated |
ABBR: IPV. A poliovirus vaccine recommended for the prevention of paralytic poliomyelitis. The vaccine, which contains inactivated types I, II, and III polioviruses, is suitable for parenteral administration to a
Ãâó:
|
| poliovirus vaccine, live oral |
ABBR: OPV. A standard preparation of one type or a combination of the three types of live, attenuated polioviruses. In 1999, an advisory panel to the Centers for Disease Control and Prevention (CDC) recommended tha
Ãâó:
|